Evidence map›Paper›PMID 31968344›Full record

ReviewDigestion2020

Vaccination in Patients with Inflammatory Bowel Diseases.

Christine N Manser, Michel H Maillard, Gerhard Rogler, Philipp Schreiner, Florian Rieder, Silja Bühler, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Digestion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Christine N ManserDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Cantonal Hospital of Frauenfeld, Frauenfeld, Switzerland, christine.manser@stgag.ch.
Michel H MaillardDivision of Gastroenterology and Hepatology, Lausanne University Hospital, Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.
Gerhard RoglerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Philipp SchreinerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Florian RiederDepartment of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Silja BühlerDivision of Infectious Diseases, Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
Cleveland Clinic · USKantonsspital Frauenfeld · CHUniversität Hamburg · DEUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

Microbiota in Intestinal FibrosisK08DK110415 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI RIEDER, FLORIAN · 2016 to 2020
$767k
NIDDK NIH HHS K08 DK110415
6 · The paper itself

Abstract

During the course of disease, a majority of inflammatory bowel disease (IBD) patients requires long-term immunosuppressive therapy with either immunomodulatory agents, biologics, or newer immunosuppressive therapies such as Vedolizumab, a selective α4β7 inhibitor, Ustekinumab, an IL 12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. Due to this, they are at increased risk for infectious diseases, many of which are possible to prevent by vaccination. This review focuses on recommended vaccinations in IBD patients and stresses special issues which have to be paid attention to. The aim of the review is to increase gastroenterologists' awareness of the importance of vaccination and to stress why especially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination as soon as diagnosis is established.

Indexed as

Biological ProductsInflammatory Bowel DiseasesHumansUstekinumabVaccinationBiological ProductsUstekinumabCrohn’s diseaseInflammatory bowel diseaseUlcerative colitisVaccination

Identifiers

PMID31968344
PMCPMC7725278
OpenAlexW3001011162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.